Letter to 2024 NEJM Links Adenoviral Anti-PF4 to VITT

Click here for the full news release from Flinders University News: New research, led by Flinders University and international experts, has finally uncovered how a rare blood-clotting condition can occur after some COVID-19 adenovirus-based vaccines or after a natural adenovirus infection. First paragraph: To the Editor: Disorders caused by antibodies against platelet factor 4 (PF4) gained […]

Comments (0)

Arterial Thrombosis

Feb 13 2026

george

A History of Russell Viper Venom

Here’s an amusing history of RVV and Dr. Russell, who named the venom. You may retrieve the article from your medical library. Thachil J. Russell viper venom: a journey from the bedside to the bench and back to the bedside. Semin Thromb Hemost. 2024;50:115-118. doi: 10.1055/s-0043-1771269. PMID: 37506733. Abstract Russell Viper Venom (RVV) is widely […]

Comments (0)

Anticoagulant Therapy

Feb 13 2026

george

What is Red Light Therapy?

Check with your medical library for this in-depth review of red light Rx efficacy: Fan BE, Pasalic L, Hew YY, Lippi G, Favaloro EJ. Red light therapy in thrombosis and hemostasis. Semin Thromb Hemost. 2026;52:266–72. doi: 10.1055/a-2717-5157. PMID: 41062078. Abstract Red light therapy is emerging as a potential non-pharmacological modulator of thrombosis and hemostasis. Photobiomodulation […]

Antiplatelet Therapy

Enhanced Coagulation Potential FVIII

See this open-access article that describes a synthetic enhanced coagulation potential FVIII. This preparation reflects the enhanced activity FIX Padua. Kashiwakura Y, Nakajima Y, Horinaka K, et al. Engineered coagulation factor VIII with enhanced secretion and coagulation potential for hemophilia A gene therapy. Blood. 2026;147:402–15. doi: 10.1182/blood.2025028481. PMID: 41198051. Abstract Click here for the visual […]

Bleeding Disorders

Normalized Activated Protein C Sensitivity Ratio Predicts VTE in OCR

Here is an open-access report on a noteworthy primary research piece detailing an assay that predicts VTE risk associated with oral contraceptives: Morimont L, Creinin MD, Gaspard U, Foidart JM, and Douxfils J. Predicting venous thromboembolism risk from an endogenous thrombin potential-based normalized activated protein C sensitivity ratio assay: toward early assessment of combined oral […]

Thrombophilia

ADAMTS-13 Conformation

What if we’ve been monitoring the wrong biomarker in iTTP remission? In immune-mediated TTP, we obsess over ADAMTS13 activity to predict relapse. But what if activity isn’t the earliest warning sign? A fascinating new study suggests the real signal may be hiding in ADAMTS13 conformation. Here is the open-access link: Joly BS, Roose E, Dekimpe […]

Thrombophilia

Review: VWD Type 2A

From Emmanuel Favaloro, PhD, Editor-in-Chief, Seminars in Thrombosis and Hemostasis: 2026 marks the 100th anniversary of the initial publication of a bleeding disorder, “pseudo-hemophilia’ that was later to become known as von Willebrand disease. Seminars in Thrombosis and Hemostasis will publish several papers on VWD in 2026. This is the first one in the queue–on […]

Bleeding Disorders

Review: Hemostasis Biomarkers

Here is a January 2026 comprehensive review of commonly used and esoteric hemostasis disorder biomarkers in downloadable format: Reardon B, Pasalic L, Favaloro EJ. Biomarkers of coagulation disorders—where to from here? Biomolecules 2026: 16, 235. https://doi.org/10.3390/biom16020235. Abstract Disorders of thrombosis and bleeding contribute to a significant morbidity and mortality burden worldwide. Correctly identifying contributing factors […]

Comments (0)

Global Hemostasis Assays

Feb 4 2026

george

Review: Clot Waveform Analysis

Click this open-access article that reviews attempts at harmonization of clot waveform analysis: Tan JY, De Guzman MRT, Wong WH, et al. Decoding clot waveform analysis: toward better understanding and harmonization. Semin Thromb Hemost. 2026. doi: 10.1055/a-2778-9810. PMID: 41506647. Abstract Clot waveform analysis (CWA) extends routine coagulation assays (activated partial thromboplastin time [PTT] and prothrombin […]

Screening Assays

Thrombophilia Testing After Provoked DVT

Following 2023 ASH guidelines, should facilities proceed with thrombophilia screening for patients who develop VTE following transient triggers? Here is an open-access essay on the effects of the ASH guidelines that appears in the January 1, 2026, issue of Clinical Laboratory News, an ADLM publication. Click “Does Provoked VTE Warrant Thrombophilia Testing?“

Comments (0)

Thrombophilia

All Posts

Letter to 2024 NEJM Links Adenoviral Anti-PF4 to VITT

A History of Russell Viper Venom

What is Red Light Therapy?

Enhanced Coagulation Potential FVIII

Normalized Activated Protein C Sensitivity Ratio Predicts VTE in OCR

ADAMTS-13 Conformation

Review: VWD Type 2A

Review: Hemostasis Biomarkers

Review: Clot Waveform Analysis

Thrombophilia Testing After Provoked DVT

George Fritsma MS MLS

Cheat Sheets from George

Questions or Comments?

Quick Question